BPC-157 vs GHK-Cu
BPC-157 is a synthetic pentadecapeptide whose sequence corresponds to a fragment of a protein found in gastric juice, and its evidence base is overwhelmingly rodent work on tendon, ligament, muscle and gastrointestinal injury. GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous human plasma tripeptide whose literature reaches back to the 1970s and is concentrated in fibroblast collagen synthesis, extracellular-matrix gene expression and topical skin research. They are commonly paired because both are marketed under a general heading of tissue repair. No study has administered both, and none has compared them in any model. Ten publications engage both compounds, and every one is a narrative or scoping review published between 2024 and 2026 that surveys the unapproved peptide market. That is an unusual pattern: the only literature connecting these two peptides is the literature written to caution clinicians about them. Any direct comparison is therefore indirect, drawn from separate studies in different tissues, species and decades.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published experiment has administered BPC-157 and GHK-Cu together, tested one against the other, or measured both in a shared model. PubMed title and abstract searches combining every published name for each compound return seven records, and Europe PMC full-text search adds three more; all ten are narrative or scoping reviews published between 2024 and 2026, and none dosed anything. What those reviews consistently report is that both compounds sit in the same regulatory position and rest on the same tier of evidence. A PRISMA-guided scoping review in a sports medicine journal found that 67 percent of the publications it identified across six emerging peptides used preclinical animal models, that human clinical studies were limited to a handful of investigations mostly lacking robust controls, and that human data showed modest improvements at best. A narrative review in a sports medicine journal reported that many unapproved peptides show favourable tissue repair outcomes in animal models while rigorous human safety data are scarce, and discussed the placebo effect and social media amplification as mediators of perceived efficacy. An orthopaedic primer described BPC-157 findings as largely unvalidated in human trials. None of these reviews attempted a comparative efficacy judgement between the two, and none had data with which to make one.
The 10 publications that cover both
- 01Review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · Am J Sports Med · scoping review following PRISMA guidance; three independent reviewers searched PubMed for six peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu) combined with musculoskeletal tissue terms, with double screening and a third reviewer as tiebreaker
Sixty-seven percent of identified publications used preclinical animal models, most commonly rats, in which each compound showed distinct mechanisms and promising but variable effects on tendon, muscle, bone and ligament healing. Human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous designs, and human data were heterogeneous and revealed modest improvements at best for metabolic bone health and degenerative knee pain. Neither compound was administered by the reviewers.
- 02Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Med · narrative review of approved and unapproved peptides marketed directly to patients, covering AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, thymosin beta-4 and TB-500
The review reported that many unapproved peptides demonstrate favourable tissue repair and metabolic outcomes in animal models but that rigorous human safety data are scarce and there is potential for serious harm. It described a parallel grey market of unapproved compounds operating largely outside regulatory oversight, and discussed the placebo effect as a mediator of perceived peptide efficacy amplified by social media.
- 03Review2026
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Luansritisakul C, et al. · Curr Pain Headache Rep · narrative review of regenerative peptides relevant to chronic pain management, covering collagen peptides, BPC-157, thymosin beta-4, TB-500, GHK-Cu, growth hormone-related peptides and cibinetide
The review summarised proposed mechanisms, potential clinical applications, preclinical and clinical evidence, safety profiles and regulatory status for each peptide, and reported that evidence for regenerative peptides in chronic pain management remains limited. The authors noted that most of the therapies covered remain unapproved by the United States Food and Drug Administration.
- 04Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, et al. · J Am Acad Orthop Surg Glob Res Rev · narrative review integrating mechanistic signalling pathways with orthopaedic relevance across wound-healing peptides, growth hormone secretagogues, recovery-enhancing agents and neuroactive peptides
The review grouped BPC-157, TB-500 and GHK-Cu together as wound-healing peptides described as promoting angiogenesis, integrin-mediated extracellular matrix remodelling and fibroblast activation. It concluded that although preclinical studies are promising, there is a current lack of clinical trials, and emphasised safety and responsible integration into musculoskeletal care.
- 05Review2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · Am J Sports Med · narrative review based on a PubMed search of biochemical and clinical studies of injectable peptide therapies, covering BPC-157, thymosin beta-4, TB-500, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu
The review reported that BPC-157 showed potential benefits in tendon and muscle repair that are largely unvalidated in human trials, and that the single human case series describing improvement after intra-articular knee injection had significant methodological flaws and no controls. It recorded that thymosin beta-4 and TB-500 lack human orthopaedic data and remain banned in sport.
- 06Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, et al. · Front Aging · narrative review with searches of PubMed, Scopus and regulatory databases from inception to January 2026; 20 primary sources selected across nine peptides including GHK-Cu, BPC-157, TB-500, tirzepatide, epitalon and bremelanotide
The review assigned GHK-Cu to dermal regeneration and BPC-157 to tissue repair among nine peptides mapped to aging interventions. It reported that approved agents demonstrated robust safety profiles from large-scale trials while non-approved peptides showed promising preclinical and limited clinical evidence but lacked long-term safety data and systematic validation, with significant gaps in biomarkers for monitoring efficacy.
- 07Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of 106 articles retrieved from PubMed, ScienceDirect and SciELO, prioritising systematic reviews, meta-analyses and randomised controlled trials
The review grouped BPC-157 and copper glycyl-histidyl-lysine in the same regenerative and tissue-repair category, alongside thymosin beta-4, thymosin alpha-1, KPV and LL-37. It recorded GHK-Cu as available in topical and transdermal dermatological formulations and BPC-157 as predominantly parenteral, and concluded that further studies are needed before most of the newer peptides can be used safely in humans.
- 08Review2026
Emerging Biologics in Lumbar Disc Degeneration: PRP, Stem Cell Therapy, and Pharmacotherapy in Mobility Restoration and Rehabilitation
Aabedi A, Agrawal DK · J Spine Res Surg · narrative review of platelet-rich plasma, mesenchymal stem cell therapy, peptide analogues and evolving pharmacologic agents in lumbar disc degeneration
The review examined BPC-157, thymosin beta-4 and GHK-Cu together as peptide analogues with potential regenerative properties for musculoskeletal and intervertebral disc degeneration. It reported that BPC-157 preclinical work shows enhanced healing rates and angiogenic modulation in rodent tissue-damage models while human clinical data remain absent, and that specific evidence for either GHK-Cu or thymosin beta-4 in lumbar disc degeneration remains limited.
- 09Review2026
Peptide-Based Approaches for Pain Relief and Healing in Wounds
Kolodynska K, et al. · Int J Mol Sci · narrative review of topical analgesia for painful wounds and of peptides with analgesic, anti-inflammatory and regenerative activity, including delivery across compromised skin barriers
The review described GHK-Cu applied in liposomal form to burn wounds in mice as promoting angiogenesis and shortening healing time, with in vitro work showing increased endothelial cell proliferation through VEGF and FGF-2 expression. It described BPC-157 applied topically as a hydrogel to alkali-burned rat skin as accelerating healing with better granulation tissue formation and re-epithelialisation, while reporting that evidence for an analgesic effect of BPC-157 is inconsistent.
- 10Review2024
Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review
Cushman CJ, et al. · Yale J Biol Med · narrative review of oral and intra-articular peptide agents for soft tissue regeneration, selected for documented preclinical and clinical work; covered type II collagen, collagen hydrolysate, BPC-157, GHK, OP3-4, WP9QY and thymosin beta-4
The review examined BPC-157 and GHK side by side as candidate agents for soft tissue repair, describing BPC-157 as investigated in small animal models by oral, topical and intraperitoneal routes and GHK as a naturally occurring peptide of human serum, saliva and urine implicated in wound healing and skin repair. It concluded that both routes of administration face limitations in bioavailability and absorption and that the field remains in its infancy.
Side by side.
| BPC-157 | GHK-Cu | |
|---|---|---|
| Evidence maturity | Preclinical only | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 10 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic 15-amino-acid peptide whose sequence corresponds to a fragment of a protein found in gastric juice. It has no confirmed endogenous circulating counterpart of its own. | The copper(II) complex of glycyl-L-histidyl-L-lysine. GHK is an endogenous constituent of human plasma that binds copper with high affinity, so the peptide has a described physiological role independent of any product. |
| Mechanism as described in the literature | Angiogenesis associated with VEGFR2 activation and upregulation, modulation of the nitric oxide system, and cytoprotective and gut-barrier effects, with supporting changes in eNOS and COX-2 expression reported in rodent tendon and muscle models. | Stimulation of fibroblast collagen and glycosaminoglycan synthesis at picomolar to nanomolar concentrations, copper transport and chelation, and broad modulation of extracellular-matrix, antioxidant and inflammatory gene programmes. |
| Size and character of the evidence base | Several hundred rodent studies concentrated in tendon, ligament, muscle, gastrointestinal and ischaemia-reperfusion injury, much of it from a small number of closely affiliated groups, which limits independent replication. | Several decades of in vitro, animal and human work. A 2026 PRISMA systematic review screened the literature from database inception to March 2026 and identified only 20 eligible studies of GHK-Cu as a standalone aesthetic intervention, 18 preclinical and 2 randomised controlled trials. |
| Best-characterised finding | Healing of surgically created rat defects that do not heal spontaneously, including complete quadriceps transection, medial collateral ligament transection and myotendinous junction detachment. | Stimulation of collagen synthesis in cultured fibroblasts across a picomolar to nanomolar dose-response, first reported in 1988, independently of any change in cell number. |
| Human data | Two uncontrolled open-label pilot studies and one retrospective chart review, all from the same private clinic, plus one ex vivo study on surgically discarded human arterial tissue. No randomised controlled trial has been completed. | Present but thin and inconsistent. The two largest randomised trials of topical copper tripeptide, in venous stasis ulcers with 86 evaluable patients and on carbon dioxide laser-resurfaced skin with 13 completers, found no significant benefit on their objective endpoints. |
| Evidence maturity | Preclinical only. No controlled human trial exists, and 2025 and 2026 orthopaedic reviews characterise the human evidence as insufficient. | Early clinical. Controlled human trials exist, but results are mixed and most positive human reports come from uncontrolled studies of multi-ingredient formulations. |
| Recency of primary research | Active, with rodent ischaemia-reperfusion work, an ex vivo human artery study and a rat Achilles tendon comparison published in 2026. | Active, with in vitro, Caenorhabditis elegans and formulation studies published in 2025 and 2026 alongside the 2026 systematic review. |
| Basis of most marketing claims | Extrapolation from rodent transection and defect models to human tendon, ligament and muscle injury, a step no completed human trial supports. | Extrapolation from in vitro collagen and gene-expression data to topical cosmetic outcomes that the controlled trials did not confirm, with skin permeation from cosmetic vehicles poorly characterised. |
And what it does not.
No experiment has compared these two peptides, so the published record supports no ranking between them. The ten papers that engage both are narrative and scoping reviews from 2024 to 2026, and their shared message is not that one peptide outperforms the other but that both belong to a class marketed well ahead of its evidence. Beyond those reviews the two literatures are asymmetric rather than contradictory. BPC-157 has by far the larger body of animal work directly targeting the injuries it is sold for, and no controlled human data at all. GHK-Cu has a longer history, a defined endogenous role, decades of mechanistic in vitro data and a small number of controlled human trials, two of the largest of which were negative on their objective endpoints. Neither has an established human dose-response for any outcome. A reader choosing between them on published evidence is choosing between a large preclinical corpus with no human confirmation and a smaller mixed human record that has repeatedly failed to confirm the in vitro promise.
Common questions.
- Has any study given BPC-157 and GHK-Cu to the same subjects?
No. PubMed searches combining every published name for each compound return seven records, and Europe PMC full-text search adds three more. All ten are narrative or scoping reviews published between 2024 and 2026 that discuss the two peptides within a survey of emerging or unapproved peptides. None administered either compound, none reports an original experiment, and none makes a comparative efficacy judgement. There is no shared animal model, no shared cell system and no shared clinical dataset in the indexed literature.
- Why is every paper that names both compounds a review?
The two peptides come from separate research traditions that never met experimentally. GHK-Cu work grew out of plasma biochemistry and dermatology, and BPC-157 work out of gastrointestinal cytoprotection research in a small number of laboratories. They were brought into contact only when clinicians began writing about the direct-to-consumer peptide market, which is why the publications naming both are orthopaedic, sports medicine, gerontology and pain reviews assessing what is being sold rather than experiments testing anything.
- What did the scoping review in sports medicine actually find?
It searched PubMed for six peptides, including BPC-157 and GHK-Cu, combined with musculoskeletal tissue terms, using three independent reviewers and PRISMA guidance. Sixty-seven percent of identified publications used preclinical animal models, most commonly rats. Each compound showed distinct mechanisms with promising but variable effects on tendon, muscle, bone and ligament healing. Human clinical studies were limited to a handful of investigations, most lacking robust controls, and human data revealed modest improvements at best.
- Does GHK-Cu having human trials make it the better-evidenced compound?
It has more human data, but the direction of that data is not favourable. The 1992 prospective randomised evaluator-blinded trial in venous stasis ulcers found that a copper tripeptide cream did not differ from inert vehicle, while silver sulfadiazine outperformed both, and the 2006 randomised trial on laser-resurfaced skin found no significant difference on objective endpoints. A 2026 systematic review located only two randomised controlled trials of GHK-Cu as a standalone aesthetic intervention across the whole literature.
- Are the two peptides used for the same thing in the published literature?
Only partially. The BPC-157 literature is dominated by internal structural repair in rodents, covering tendon, ligament, muscle, gut and ischaemia-reperfusion injury, mostly by systemic routes. The GHK-Cu literature is dominated by skin, with fibroblast collagen synthesis, extracellular-matrix gene expression and topical formulation work, plus animal studies in lung fibrosis and a lifespan study in Caenorhabditis elegans. The overlap that the reviews describe is conceptual, in wound healing and matrix remodelling, rather than a shared body of comparable experiments.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.